<?xml version='1.0' encoding='utf-8'?>
<document id="28945011"><sentence text="Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling." /><sentence text="Schisantherin A and schisandrin A, the most abundant active ingredients of Wuzhi capsule, are known to inhibit tacrolimus metabolism by inhibiting CYP3A4/5"><entity charOffset="0-15" id="DDI-PubMed.28945011.s2.e0" text="Schisantherin A" /><entity charOffset="20-33" id="DDI-PubMed.28945011.s2.e1" text="schisandrin A" /><entity charOffset="111-121" id="DDI-PubMed.28945011.s2.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.28945011.s2.e0" e2="DDI-PubMed.28945011.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28945011.s2.e0" e2="DDI-PubMed.28945011.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28945011.s2.e0" e2="DDI-PubMed.28945011.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28945011.s2.e1" e2="DDI-PubMed.28945011.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28945011.s2.e1" e2="DDI-PubMed.28945011.s2.e2" /></sentence><sentence text=" We aimed to predict the contribution of schisantherin A and schisandrin A to drug-drug interaction (DDI) between Wuzhi capsule and tacrolimus using physiologically-based pharmacokinetic (PBPK) modelling"><entity charOffset="41-56" id="DDI-PubMed.28945011.s3.e0" text="schisantherin A" /><entity charOffset="61-74" id="DDI-PubMed.28945011.s3.e1" text="schisandrin A" /><entity charOffset="132-142" id="DDI-PubMed.28945011.s3.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.28945011.s3.e0" e2="DDI-PubMed.28945011.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28945011.s3.e0" e2="DDI-PubMed.28945011.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28945011.s3.e0" e2="DDI-PubMed.28945011.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28945011.s3.e1" e2="DDI-PubMed.28945011.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28945011.s3.e1" e2="DDI-PubMed.28945011.s3.e2" /></sentence><sentence text=" Firstly, the inhibition mechanism of schisantherin A and schisandrin A on CYP3A4/5 was investigated"><entity charOffset="38-53" id="DDI-PubMed.28945011.s4.e0" text="schisantherin A" /><entity charOffset="58-71" id="DDI-PubMed.28945011.s4.e1" text="schisandrin A" /><pair ddi="false" e1="DDI-PubMed.28945011.s4.e0" e2="DDI-PubMed.28945011.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28945011.s4.e0" e2="DDI-PubMed.28945011.s4.e1" /></sentence><sentence text=" Thereafter, PBPK models of schisantherin A, schisandrin A and tacrolimus were established"><entity charOffset="28-43" id="DDI-PubMed.28945011.s5.e0" text="schisantherin A" /><entity charOffset="45-58" id="DDI-PubMed.28945011.s5.e1" text="schisandrin A" /><entity charOffset="63-73" id="DDI-PubMed.28945011.s5.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.28945011.s5.e0" e2="DDI-PubMed.28945011.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28945011.s5.e0" e2="DDI-PubMed.28945011.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28945011.s5.e0" e2="DDI-PubMed.28945011.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28945011.s5.e1" e2="DDI-PubMed.28945011.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28945011.s5.e1" e2="DDI-PubMed.28945011.s5.e2" /></sentence><sentence text=" Finally, tacrolimus pharmacokinetics were evaluated after the combined use with schisantherin A or schisandrin A"><entity charOffset="10-20" id="DDI-PubMed.28945011.s6.e0" text="tacrolimus" /><entity charOffset="81-96" id="DDI-PubMed.28945011.s6.e1" text="schisantherin A" /><entity charOffset="100-113" id="DDI-PubMed.28945011.s6.e2" text="schisandrin A" /><pair ddi="false" e1="DDI-PubMed.28945011.s6.e0" e2="DDI-PubMed.28945011.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28945011.s6.e0" e2="DDI-PubMed.28945011.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28945011.s6.e0" e2="DDI-PubMed.28945011.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28945011.s6.e1" e2="DDI-PubMed.28945011.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28945011.s6.e1" e2="DDI-PubMed.28945011.s6.e2" /></sentence><sentence text=" The blood area under the curve (AUC) of tacrolimus increased 1"><entity charOffset="41-51" id="DDI-PubMed.28945011.s7.e0" text="tacrolimus" /></sentence><sentence text="77- and 2" /><sentence text="61-fold after a single dose and multiple doses of schisantherin A, respectively"><entity charOffset="50-65" id="DDI-PubMed.28945011.s9.e0" text="schisantherin A" /></sentence><sentence text=" Meanwhile, schisandrin A inhibited tacrolimus metabolism to a smaller extent"><entity charOffset="12-25" id="DDI-PubMed.28945011.s10.e0" text="schisandrin A" /><entity charOffset="36-46" id="DDI-PubMed.28945011.s10.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.28945011.s10.e0" e2="DDI-PubMed.28945011.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28945011.s10.e0" e2="DDI-PubMed.28945011.s10.e1" /></sentence><sentence text=" Also, it showed that mechanism-based inhibition (MBI) played a more important role in DDI than reversible inhibition after long-term administration, while reversible inhibition was comparable to MBI after single-dose administration" /><sentence text=" In conclusion, we utilized PBPK modelling to quantify the contribution of schisantherin A and schisandrin A to DDI between tacrolimus and Wuzhi capsule"><entity charOffset="75-90" id="DDI-PubMed.28945011.s12.e0" text="schisantherin A" /><entity charOffset="95-108" id="DDI-PubMed.28945011.s12.e1" text="schisandrin A" /><entity charOffset="124-134" id="DDI-PubMed.28945011.s12.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.28945011.s12.e0" e2="DDI-PubMed.28945011.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28945011.s12.e0" e2="DDI-PubMed.28945011.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28945011.s12.e0" e2="DDI-PubMed.28945011.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28945011.s12.e1" e2="DDI-PubMed.28945011.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28945011.s12.e1" e2="DDI-PubMed.28945011.s12.e2" /></sentence><sentence text=" This may provide more insights for the rational use of this drug combination" /><sentence text="" /></document>